公开(公告)号：US20240082337A1

公开(公告)日：2024-03-14

申请号：US18509499

申请日：2023-11-15

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Jaehoon YOU ,  Jong Lae LIM

IPC分类号： A61K36/54 ,  A23L33/105

CPC分类号： A61K36/54 ,  A23L33/105

摘要： The present invention relates to a pharmaceutical or food composition comprising Cinnamomum cassia pretreated extract exhibiting an excellently enhanced pharmacological effect than Cinnamomum cassia extract prepared by a conventional common extraction method of Cinnamomum cassia and extract prepared with Cinnamomum cassia single herb medicine, or a method for preventing, improving or treating gastritis or peptic ulcer using the composition. In addition, the present invention relates to a preparation method of Cinnamomum cassia pretreated extract which is characterized by pretreating Cinnamomum cassia with a non-polar solvent and extracting it with a polar solvent.

公开(公告)号：US11813285B2

公开(公告)日：2023-11-14

申请号：US16965748

申请日：2019-01-09

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Jong Seo Choi ,  Min Soo Kim ,  Shin Jung Park ,  Jong Lae Lim

IPC分类号： A61K33/00 ,  A61K31/4439

CPC分类号： A61K33/00 ,  A61K31/4439

摘要： The present invention relates to a stable pharmaceutical composition comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate. Specifically, the present invention relates to a pharmaceutical composition with improved stability comprising a low dose of sodium bicarbonate, so that it has improved dissolution rate and bioavailability and also reduces side effects resulting from a high dose of sodium bicarbonate.

公开(公告)号：US20230084129A1

公开(公告)日：2023-03-16

申请号：US17801057

申请日：2021-02-18

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： Jong Seo Choi ,  Min Soo Kim ,  Shin Jung Park

IPC分类号： A61K31/4439 ,  A61K47/02 ,  A61K9/08 ,  A61P1/04

摘要： The present invention relates to a pharmaceutical preparation comprising omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention relates to a pharmaceutical preparation, wherein a first mixed part comprising esomeprazole comprises 40% by weight or less of sodium bicarbonate based on the total weight of sodium bicarbonate comprised in the preparation, and thus sodium bicarbonate is first dissolved so as to raise pH, and then esomeprazole is dissolved such that the release properties of an active ingredient are improved, and thus the dissolution pattern and bioavailability of a drug can be enhanced.

公开(公告)号：US20220008414A1

公开(公告)日：2022-01-13

申请号：US17296008

申请日：2019-11-22

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： Young II Choi ,  Nina Ha ,  Ju Young Song ,  Min Cheol Kim ,  Daekwon Bae ,  Ji Yeon Baek

IPC分类号： A61K31/496 ,  A61P25/02 ,  A61K31/495

摘要： The present invention relates to a pharmaceutical composition for preventing or treating CMT disease, comprising histone deacetylase 6 inhibitor. The pharmaceutical composition according to the present invention has histone deacetylase 6 (HDAC6) inhibitory activity and thus is effective in preventing or treating CMT disease.

公开(公告)号：US10584117B2

公开(公告)日：2020-03-10

申请号：US15748081

申请日：2016-07-27

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： Jaekwang Lee ,  Moo Sung Ko ,  Younghue Han ,  Yuntae Kim

IPC分类号： C07D413/10 ,  A61K31/4245 ,  C07D413/12 ,  C07D271/10 ,  C07D205/04 ,  C07D213/02

摘要： The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

公开(公告)号：US10287255B2

公开(公告)日：2019-05-14

申请号：US15125256

申请日：2015-03-12

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Hyeseung Song ,  Changgon Lee ,  Dalyong Kwak ,  Jaeyoung Lee ,  Suyeal Bae ,  Yuntae Kim ,  Daekwon Bae ,  Nina Ha ,  Miseon Bae ,  Jihyun Kim

IPC分类号： C07D241/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D405/10 ,  C07D405/12 ,  C07D409/06 ,  C07D409/10 ,  C07D413/06 ,  C07D413/10 ,  A61K31/496 ,  A61K31/5375

摘要： A compound of formula (I), having histone deacetylase 6 (HDAC6) inhibitory activity, wherein X, Q, N, R1, R2, L, and n are as described, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

公开(公告)号：US09994627B2

公开(公告)日：2018-06-12

申请号：US14352734

申请日：2012-09-28

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Yeo-Wook Koh ,  Sang-Yong Lee ,  Cook-Hee Kim ,  Seung-Hui Lee ,  Ha-Na Kim ,  Su-Yon Kim ,  Jin-Hyun Seong ,  Yong-Hyun Cho

IPC分类号： C07K14/505 ,  C07K1/14 ,  C07K1/16 ,  C12N5/00 ,  C12N15/00

CPC分类号： C07K14/505 ,  C07K1/14 ,  C07K1/16 ,  C12N5/00 ,  C12N15/00

摘要： The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an N-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost.

公开(公告)号：US09776987B2

公开(公告)日：2017-10-03

申请号：US15039226

申请日：2014-11-25

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Yuntae Kim ,  ChangSik Lee ,  DaeKyu Choi ,  MooSung Ko ,  Younghue Han ,  SoYoung Kim ,  JaeKi Min ,  DoHoon Kim

IPC分类号： C07D401/12 ,  C07D401/14

CPC分类号： C07D401/12 ,  C07D401/14

摘要： The present invention relates to novel amide derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel amide derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.

公开(公告)号：US09447083B2

公开(公告)日：2016-09-20

申请号：US14424749

申请日：2013-08-29

申请人： CHONG KUN DANG PHARMACEUTICAL CORP. ,  INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

发明人： HoJin Choi ,  JaeWon Lee ,  ChangGon Lee ,  NiNa Ha ,  Su Kil Seo ,  SunMi Lee ,  Song-Min Lee

IPC分类号： C07D409/12 ,  C07D209/08 ,  C07D409/14 ,  C07D403/12 ,  C07D401/14 ,  C07D235/08 ,  C07D401/12 ,  C07D405/12 ,  C07D285/14

CPC分类号： C07D409/14 ,  C07D209/08 ,  C07D235/08 ,  C07D285/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12

摘要： The present invention relates to novel N-acylhydrazone derivatives, and more particularly to novel N-acylhydrazone derivatives having selective T cell inhibitory activity and/or anti-lymphoid malignancy activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, the use thereof for preparing pharmaceutical compositions, pharmaceutical compositions containing the same, treatment methods using the compositions, and methods for preparing the novel N-acylhydrazone derivatives.

摘要翻译： 本发明涉及新的N-酰腙衍生物，更具体地说，涉及具有选择性T细胞抑制活性和/或抗淋巴恶性肿瘤活性的新型N-酰腙衍生物，其立体异构体，其药学上可接受的盐，其制备药物组合物的用途 ，含有该组合物的药物组合物，使用该组合物的治疗方法，以及制备新N-酰腙衍生物的方法。

公开(公告)号：US09371294B2

公开(公告)日：2016-06-21

申请号：US14110271

申请日：2012-04-12

申请人： SeoHee Lee ,  Jung Taek Oh ,  JaeKwang Lee ,  JaeWon Lee ,  Suyeal Bae ,  Nina Ha ,  Sera Lee

发明人： SeoHee Lee ,  Jung Taek Oh ,  JaeKwang Lee ,  JaeWon Lee ,  Suyeal Bae ,  Nina Ha ,  Sera Lee

IPC分类号： C07D401/14 ,  C07D403/10 ,  C07D405/14 ,  C07D263/24 ,  C07D263/16 ,  C07D263/22 ,  C07D401/06 ,  C07D413/06 ,  C07D413/08 ,  C07D413/10 ,  C07D417/12

CPC分类号： C07D263/24 ,  C07D263/16 ,  C07D263/22 ,  C07D401/06 ,  C07D413/06 ,  C07D413/08 ,  C07D413/10 ,  C07D417/12

摘要： The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.

摘要翻译： 本发明涉及环烯基芳基衍生物，其异构体，其药学上可接受的盐，其水合物或溶剂合物; 制备衍生物的方法; 和含有它们的药物组合物。 本发明的化合物显示CETP活性抑制的作用。 这意味着这些化合物可以增加HDL-胆固醇并降低LDL-胆固醇。